Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca A Lotta

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Lancet (London, England)|January 18, 2011
Addressing the complexity of cardiovascular disease by designLuca A Lotta, Flora Peyvandi
Lancet (London, England)|June 20, 2018
Genomic insights into the causes of type 2 diabetesClaudia Langenberg, Luca A Lotta
The Lancet. Diabetes & Endocrinology|September 21, 2017
PCSK9 inhibition and type 2 diabetesLuca A Lotta, Simon J Griffin
Haematologica|September 3, 2010
Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpuraFlora Peyvandi, Roberta Palla, Luca A Lotta
The New England Journal of Medicine|September 14, 2012
Prothrombin mutation conveying antithrombin resistanceLuca A Lotta, Ida Martinelli, Flora Peyvandi
The New England Journal of Medicine|July 18, 2009
Inhibitors of factor VIII in hemophiliaFlora Peyvandi, Luca A Lotta, Pier M Mannucci
The Journal of Tehran Heart Center|October 18, 2012
Genome-wide association studies in myocardial infarction and coronary artery diseasePier Mannuccio Mannucci, Luca A Lotta, Flora Peyvandi
Current Diabetes Reports|May 21, 2018
Prioritising Risk Factors for Type 2 Diabetes: Causal Inference through Genetic ApproachesLaura B L Wittemans, Luca A Lotta, Claudia Langenberg
Human Mutation|October 23, 2009
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Isabella Garagiola, Roberta Palla, et al.
Blood Reviews|February 19, 2013
The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Khaled M Musallam, et al.
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|January 18, 2011
Addressing the complexity of cardiovascular disease by designLuca A Lotta, Flora Peyvandi
Lancet (London, England)|June 20, 2018
Genomic insights into the causes of type 2 diabetesClaudia Langenberg, Luca A Lotta
The Lancet. Diabetes & Endocrinology|September 21, 2017
PCSK9 inhibition and type 2 diabetesLuca A Lotta, Simon J Griffin
Haematologica|September 3, 2010
Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpuraFlora Peyvandi, Roberta Palla, Luca A Lotta
The New England Journal of Medicine|September 14, 2012
Prothrombin mutation conveying antithrombin resistanceLuca A Lotta, Ida Martinelli, Flora Peyvandi
The New England Journal of Medicine|July 18, 2009
Inhibitors of factor VIII in hemophiliaFlora Peyvandi, Luca A Lotta, Pier M Mannucci
The Journal of Tehran Heart Center|October 18, 2012
Genome-wide association studies in myocardial infarction and coronary artery diseasePier Mannuccio Mannucci, Luca A Lotta, Flora Peyvandi
Current Diabetes Reports|May 21, 2018
Prioritising Risk Factors for Type 2 Diabetes: Causal Inference through Genetic ApproachesLaura B L Wittemans, Luca A Lotta, Claudia Langenberg
Human Mutation|October 23, 2009
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Isabella Garagiola, Roberta Palla, et al.
Blood Reviews|February 19, 2013
The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Khaled M Musallam, et al.
Pageof 11